283
Views
3
CrossRef citations to date
0
Altmetric
Letters to the Editor

Daratumumab is safe and induces a rapid hematological response in light-chain amyloidosis with severe cardiac impairment

, , , , , , , , , , , , , & show all
Pages 979-983 | Received 06 Nov 2020, Accepted 08 Jul 2020, Published online: 29 Nov 2020
 

Disclosure statement

Louise Roulin received lecture fees from Janssen. Alizée Maarek received lecture fees from Takeda and Sandoz. Corinne Haioun received consulting or lecture fees from Roche, Celgene, Janssen, Gilead, Takeda, Novartis, Amgen as well as travel accommodations from Roche, Celgene, Amgen. Karim Belhadj received consulting or lecture fees from Takeda, Amgen, Celgene, Janssen. The remaining authors declare no competing financial interests.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.